Eight Roads launches $250m China healthcare fund

The Eight Roads China Healthcare Fund will allocate 40% of its corpus to therapeutics, a statement said. Other focus areas include healthcare services, digital health, and medical technology. The private equity firm also plans to launch a dedicated China technology fund.

“Eight Roads has backed innovative China healthcare companies since 1995. The launch of this specialized fund reflects our confidence in the evolution of the China market and forms part of a strategy to more precisely target our healthcare and technology expertise,” said Daniel Auerbach, a senior managing partner at Eight Roads.

Driven by an aging population, increasing patient demands, and supportive government policies, the investor sees a growing opportunity in the healthcare sector. The firm believes its patient capital approach is suited to the long development times typically required for healthcare companies, especially those focusing on new drug development.

Eight Road manages $3.6 billion of capital under its associated funds, with offices in China, Japan, Uk, India and the US. Over the past 22 years, the firm has invested in more than 100 healthcare companies, over 30 of which are in China.

These investments span the healthcare value chain, from drug discovery companies WuXi AppTec and Hua Medicine to biologic player Innovent Biologics to hospital services providers DeltaHealth and Bang Er Orthopedic Hospital. Shanghai-based DeltaHealth is a greenfield hospital built by Eight Roads, specializing in cardiovascular treatment.

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Fundraising
• Healthcare
• Early-stage
• China
• Eight Roads